A little more than a year after the White House announced the Precision Medicine Initiative, researchers at Penn and across the nation are optimistic about the future of clinical treatment for Alzheimer’s disease.
The “all-in approach” taken by federal agencies “could not be happening at a more opportune time,” said Cynthia Bens, executive director of Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD), which hosted a panel discussion on precision medicine Monday. More than 5 million Americans suffer from Alzheimer’s disease today, and that number is expected to more than triple by 2050, Bens said. Click here to listen to the complete presentation.